Anticancer 'nanoswitch' technology shows promise in animal model of triple-negative breast cancer, colorectal cancer

AI Summary

Researchers led by Professor Yoosoo Yang developed an advanced anticancer 'nanoswitch' technology that enhances immunotherapy by targeting and neutralizing substances from cancer cells while boosting immune response. The innovation shows promise in treating triple-negative breast and colorectal cancers in animal models.

A research team led by Professor Yoosoo Yang (Department of Integrative Biotechnology) of Sungkyunkwan University, in collaboration with the Korea Institute of Science and Technology (KIST) and Incheon National University, has developed a next-generation anticancer immunotherapy technology that targets and eliminates key substances released by cancer cells while simultaneously boosting the patient's immune response.